TMates

TMates is priced at $199/month flat, the same rate at every dose, with no step-up fees as your dosage escalates during titration. This flat-rate model means you can budget the full cost of your program without worrying about increases at therapeutic doses. 24/7 doctor access and virtual check-in appointments are included.

Yes. TMates provides 24/7 access to U.S.-based doctors across all 50 states, actual physician availability, not just asynchronous messaging support. This is particularly valuable for patients new to GLP-1 therapy who have questions about injection technique, side effects, or dose adjustments between scheduled check-ins.

Yes. TMates is a licensed telehealth platform with U.S.-based doctors in all 50 states, prescribing clinically dosed compounded semaglutide formulated in U.S. facilities. Its medication is compounded, not an FDA-approved finished product, but uses the same active ingredient as Ozempic and Wegovy.

TMates medications are formulated in U.S.-based facilities, which the platform highlights as a quality and reliability assurance. Combined with clinically dosed compounded semaglutide and oversight from U.S.-based doctors, this gives patients a domestic-sourcing point of confidence.

No. TMates operates on a direct-pay model and does not bill insurance, which is standard for compounded GLP-1 telehealth. The benefit is its transparent flat $199/month pricing with no step-up fees and no prior-authorization delays.

TMates competes on clinical supervision rather than price, its 24/7 U.S.-based doctor access exceeds the messaging-only support at most competitors. At $199/month flat it costs more than Embody ($69), Novi ($133), and TrimRx ($149), but like those it avoids dose-based price escalation. It is best for patients who want ongoing physician availability that mirrors a traditional outpatient program.